Skip to main content
. 2015 Feb 6;24(12):1471–1482. doi: 10.1089/scd.2014.0568

Table 2.

Allogeneic Hematopoietic Stem Cell-Transplanted Patients

UPN# Sex Age at DSC treatment, years Indication for DSC treatment No. of DSC infusions DSC treatment (weeks after HSCT) FCXM test
1011 M 8 cGVHD 2 398, 406 Neg
1265 M 18 cGVHD 2 195, 206 Neg
1462 F 65 aGVHD 2 16, 31 Pos
1468 M 58 aGVHD 1 15 Neg
1475 F 18 cGVHD 1 45 Neg
1504 F 53 aGVHD 3 6, 15, 19 Neg
1531 M 62 aGVHD 1 4 Neg
1563 F 8 HC 1 13 Neg
1583 M 58 Toxicity, aGVHD 2 1, 7 Pos
1587 F 41 HC 1 9 Neg
1588 F 24 HC 1 8 Neg
1589 M 48 aGVHD 3 44, 46, 47 Neg
1590 F 43 HC 1 5 Neg
1602 M 44 HC 1 6 Neg
1619 F 43 aGVHD 4 21, 22, 23, 39 Neg
1620 M 53 aGVHD 5 16, 17, 18, 23, 44 Neg

UPN, unique patient number; aGVHD, acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; HC, hemorrhagic cystitis.